IONIQ Sciences Recognized with 2020’s “Most Innovative Non-Invasive Lung Cancer Testing Solution” by Global 100
IONIQ Sciences has been recognized by Global 100 as having 2020’s “Most Innovative Non-Invasive Lung Cancer Testing Solution.” This year has seen our IONIQ ProLung Test™ receive widespread recognition for its life-saving potential, including a “Breakthrough Device” designation from the FDA. Global 100 is the latest to highlight our IONIQ ProLung Test’s unique potential to offer a truly non-invasive solution to the uncertainties of treating the world’s deadliest cancer. Our mission to leverage this revolutionary bioimpedance technology in the development of a Multi-Cancer Screen is further affirmed by these continued accolades. We’re proud of what we’ve accomplished so far and determined to continue the fight against the scourge of cancer.